Combination regimen in the treatment of chronic prostatitis.
The aim of the study was to report our experiences in the treatment of chronic prostatitis using combination regimen including ciprofloxacin, doxazosin, allopurinol and biofeedback perineal massage. From May 2003 to April 2004, 7 patients with NIH Category II-chronic bacterial prostatitis and 7 patients with NIH Category IIIA-inflammatory chronic pelvic pain syndrome were treated. The NIH-Chronic Prostatitis Symptom Index (NIH-CPSI) was scored by the patient before and after the treatment, 6 months later. In Category II patients, the bacterial eradication rate was 71% after ciprofloxacin treatment during a follow-up of 6 months. The beneficial response rate to allopurinol, doxazosin and biofeedback perineal massage was 50%, 42% and 85%, respectively. In NIH Category IIIA patients, the individual beneficial response rate to ciprofloxacin, allopurinol, doxazosin and biofeedback perineal massage was 57%, 100%, 71% and 100%, respectively. Comparing pre-treatment and post-treatment results of the combination regimen, there was a statistically significant improvement in the 3 domains of pain score, urinary symptoms and quality of life impact of the NIH-CPSI. Combination regimen including ciprofloxacin, doxazosin allopurinol and biofeedback perineal massage in the treatment of chronic prostatitis is a safe and effective modality in our limited experience.
Chen
W-M
WM
Division of Urology, Department of Surgery, Taichung Veterans General Hospital, National Yang-Ming University School of Medicine, Taipei, Taiwan, Republic of China.
Yang
C-R
CR
Ou
Y-C
YC
Ho
H-C
HC
Su
C-K
CK
Chiu
K-Y
KY
Cheng
C-L
CL
D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use; D000328:Adult; D000368:Aged; D000493:Allopurinol / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D002939:Ciprofloxacin / Q000627:therapeutic use; D003131:Combined Modality Therapy; D017292:Doxazosin / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D006074:Gout Suppressants / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008405:Massage; D008875:Middle Aged; D011472:Prostatitis / Q000188:drug therapy / Q000628:therapy*
D000317:Adrenergic alpha-Antagonists; D000900:Anti-Bacterial Agents; D006074:Gout Suppressants; D002939:Ciprofloxacin; D000493:Allopurinol; D017292:Doxazosin